9/8/2022 7:17:47 AM
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial Of AXS-05 In Alzheimer’s Disease Agitation
8/19/2022 6:57:01 AM
Axsome Therapeutics: FDA Approves AUVELITY Extended-release Tablets For Major Depressive Disorder In Adults
5/31/2022 7:58:43 AM
Axsome Announces Publication Of Pivotal GEMINI Phase 3 Trial Of AXS-05 In Major Depressive Disorder
5/18/2022 7:20:20 AM
Axsome Therapeutics Publishes ASCEND Phase 2 Trial Of AXS-05 In MDD In American Journal Of Psychiatry
5/9/2022 7:36:00 AM
Jazz Pharma Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics
5/2/2022 7:10:06 AM
Axsome Therapeutics Q1 Net Loss $39.6 Mln Vs. Net Loss $29.3 Mln Last Year
5/2/2022 7:07:03 AM
Axsome Therapeutics Gets FDA Complete Response Letter For NDA For AXS-07 For Acute Treatment Of Migraine
3/28/2022 6:12:19 AM
Axsome Therapeutics Enters Agreement To Acquire Sunosi From Jazz Pharma